- Home
- LNKB vs OBIO Comparison
LNKB vs OBIO Comparison
Compare LNKB & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- OBIO
- Stock Information
- Founded
- LNKB 2018
- OBIO 2017
- Country
- LNKB United States
- OBIO United States
- Employees
- LNKB N/A
- OBIO N/A
- Industry
- LNKB
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- LNKB
- OBIO Health Care
- Exchange
- LNKB Nasdaq
- OBIO Nasdaq
- Market Cap
- LNKB 236.7M
- OBIO 200.5M
- IPO Year
- LNKB N/A
- OBIO N/A
- Fundamental
- Price
- LNKB $6.54
- OBIO $5.42
- Analyst Decision
- LNKB Hold
- OBIO Strong Buy
- Analyst Count
- LNKB 1
- OBIO 4
- Target Price
- LNKB $7.50
- OBIO $15.75
- AVG Volume (30 Days)
- LNKB 40.5K
- OBIO 53.5K
- Earning Date
- LNKB 10-25-2024
- OBIO 11-11-2024
- Dividend Yield
- LNKB 4.53%
- OBIO N/A
- EPS Growth
- LNKB N/A
- OBIO N/A
- EPS
- LNKB N/A
- OBIO N/A
- Revenue
- LNKB $68,142,000.00
- OBIO $2,079,000.00
- Revenue This Year
- LNKB N/A
- OBIO $7.68
- Revenue Next Year
- LNKB $4.03
- OBIO $110.40
- P/E Ratio
- LNKB N/A
- OBIO N/A
- Revenue Growth
- LNKB 101.22
- OBIO N/A
- 52 Week Low
- LNKB $5.86
- OBIO $4.22
- 52 Week High
- LNKB $8.29
- OBIO $11.69
- Technical
- Relative Strength Index (RSI)
- LNKB 55.81
- OBIO 53.12
- Support Level
- LNKB $6.36
- OBIO $4.96
- Resistance Level
- LNKB $6.68
- OBIO $5.99
- Average True Range (ATR)
- LNKB 0.15
- OBIO 0.36
- MACD
- LNKB 0.03
- OBIO 0.12
- Stochastic Oscillator
- LNKB 73.08
- OBIO 57.14
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.